30 June 2020 in Cukurova Medical Journal
Purpose: This study was carried out to assess the rate and pattern of adverse drug reactions (ADRs) reporting in hospitalized patients at a teaching hospital. Materials and Methods: A retrospective cross-sectional study was conducted in Balcalı Hospital at Adana, Turkey for one year. The reports were examined on the basis of demographics, ADRs type, causality, severity, seriousness, drug characteristics, and outcomes. WHO-UMC/ Naranjo algorithm scale, Hartwig and Siegel severity scale and pharmacovigilance contact point (PVCP) criteria were used to assess the causality, severity, and seriousness of ADRs respectively. Results: A total of 61105 hospitalized patients were admitted to the hospital and only 20 spontaneous ADRS were submitted to (PVCP) with an incidence rate of 0.03%. Of these, 18 eligible ADRs reporting forms were reviewed according to inclusion criteria. ADRs related to antibiotics (38.8%) were most frequently reported followed by antineoplastic agents (22.2%). Most of the ADRs were related to skin (33.3%). In causality assessment, almost 50% of the reported ADRs were possible and 55.5% were moderate in severity. Moreover, about 83.3% of the ADRs were found to be serious according to PVCP criteria. Among the total patients, 55.5% have recovered from the reactions. ADRs were reported by physicians (66.7%) followed by an assistant doctor (16.7%).Conclusion: This study shows that ADRs are a significant problem in hospitalized patients. Monitoring and management of severe and serious types of ADRs would be valuable for improved patient care.
29 December 2019 in Cukurova Medical Journal
Migren, çocukluk, ergenlik veya erken erişkin dönemde başlayan, sıklıkla bulantı, ışık ve ses duyarlılığı gibi semptomların eşlik ettiği, periyodik aralıklarla gelen zonklayıcı karakterde bir baş ağrısı türüdür. Migrenli hastalarda en çok görülen psikiyatrik bozukluklarda ilk sırada depresyon yer almaktadır. Migren ve depresyon birçok kişiyi etkiler ve yaklaşık %10-15 dolayında benzer prevalansa sahiptir. Migren tedavisi eğer eksik yapılırsa durumun kontrol edilemez olmasının getirdiği çaresizliğin sonucunda hastalarda depresyon ortaya çıkabilmektedir. Migrenin akut ataklarının profilaksi ve tedavisi iki aşamada gerçekleştirilmektedir. Akut atakta; analjezikler ve non-steroid antiinflamatuar ilaçlar, ergot alkoloidleri ve triptanlar kullanılırken, profilaktik tedavide; beta blokörler, antiepileptikler, antidepresanlar, kalsiyum kanal blokörleri gibi ilaçlar kullanılmaktadır. Bu ilaçlarla hastalarda atakların sayısının ve şiddetinin azaltılmasında tam bir başarı elde edilememektedir. Bu sebeple son zamanlarda antidepresan ilaç gruplarının tedavideki yeri araştırılmaktadır. Özellikle depresyon, stres, anksiyete ve uyku bozukluğu ile birlikte sık migren atağı geçirenlerin, profilaktik farmakolojik tedavisinde başta trisiklik antidepresanlar (TSA) olmak üzere, selektif serotonin geri alım inhibitörleri (SSRI) ve selektif serotonin-noradrenalin geri alım inhibitörleri (SNRI) tercih edilmektedir. Bu çalışmamızda migren tedavisinde kullanılan antidepresanların migrenin şiddeti ve süresindeki etkilerini incelemek amaçlanmıştır.
30 March 2023 in European Journal of Therapeutics
Introduction: The purpose of this study was to assess dental care professionals' drug prescription knowledge, practices, and reporting of adverse drug reactions (ADRs). Methods: A cross-sectional exploratory study was conducted by using a face-to-face survey administered to a sample of dentists from tertiary care hospitals in Adana, Türkiye. A questionnaire consisted of six sections with closed-ended items including sociodemographic characteristics, knowledge about drugs, patient history information, counseling practices during prescribing, source of information and ADR reporting. Results: The study included 180 dentists, with a 95.3% response rate. More than half of the dentists (50.6%) stated their level of knowledge about drug price/cost as low. Most of the dentists (50.6%;n=91) claimed that they never/rarely asked about health insurance during patient history information. Moreover, most of the participants reported that they never/rarely and sometimes counsel the patients regarding drug mechanism of action, side effects of the drug, interaction of prescribed drug with other drugs/nutrients. It was determined that the dentists learned about the drugs from Vademecum (Turkish Medication Guidebook: 70%;n=126) and the internet (55%;n=99). A higher proportion (85.5%) of the dentists indicated that they did not report ADR during their clinical practice. Conclusion: This study showed a general improvement in dentists prescribing knowledge and practices, although they reported some lack of knowledge regarding drug cost, discussion about the possible side effect of a drug/interaction with other drugs/nutrients with patients and under-reporting of ADRs. Periodic education and training for dentists are critical to overcoming any problem related to prescribing errors and potential ADRs.
14 August 2026 in Journal of Human Genetics
30 August 2025 in Vita Medica Scientica Journal (VMS Journal))
Objective and Aim The COVID‑19 pandemic has been associated with increased psychological distress worldwide. Understanding antidepressant utilization during this period is important for understanding burden of depression on public health and rational prescribing and public health planning. To characterize antidepressant use habits during the COVID‑19 pandemic in Turkey and identify sociodemographic correlates, including self‑medication behaviors and adverse effects. Material and Methods Cross‑sectional, observational online survey among adults (≥18 years) via Google Forms. The questionnaire captured socio‑demographics, chronic diseases, and antidepressant‑use characteristics. A total of 420 respondents completed the survey. Analyses were performed in IBM SPSS v23 using chi‑square–based tests and non‑parametric comparisons; statistical significance was set at p<0.05. Ethics approval: Çukurova University Faculty of Medicine Non‑Interventional Clinical Research Ethics Committee (Meeting No: 110; 2 April 2021). Results Mean age 37.97±10.55 years (18–70); 66.7% women; 26.9% had ≥1 chronic disease. Lifetime antidepressant use was 67.2%; 78.6% used psychiatrist‑prescribed medications; 37.1% reported adverse effects. Antidepressant use differed by education and employment (higher among middle‑school graduates and those not employed; p<0.05); it was more frequent among men; no association was observed with age. Conclusions Antidepressant utilization appeared to rise during the COVID‑19 period and was linked to socioeconomic stressors such as unemployment. The substantial proportion reporting adverse effects underscores the need for rational use and pharmacovigilance. These findings can inform targeted mental‑health support during and after public‑health crises. Keywords: COVID‑19, Antidepressive Agents, Drug Utilization, Self‑Medication, Cross‑Sectional Studies.